PerkinElmer to acquire Horizon Discovery for $383M

By The Science Advisory Board staff writers

November 2, 2020 -- PerkinElmer has reached an agreement to acquire Horizon Discovery Group with an all-cash offer of approximately $383 million. The transaction is expected to close in the first quarter of 2021.

With this acquisition, PerkinElmer will expand its portfolio of automated life sciences discovery and applied genomics technologies including gene editing and gene modulation tools. This will complement PerkinElmer's existing products including immunoassay platforms, high-content screening and in vivo imaging, microfluidics, robotic liquid-handling technologies, and next-generation sequencing library preparation kits.

PerkinElmer will be able to better partner with academic, pharmaceutical, and biopharmaceutical scientists to provide tools for exploring next-generation cell engineering and customized cell lines for precision medicine.

Horizon is headquartered in Cambridge, U.K. and is a producer of CRISPR and RNA interference reagents, cell models, cell engineering, and base editing technologies. The company has approximately 400 employees in multiple countries and reported revenue of $75.5 million in 2019.

PerkinElmer introduces no-wash immunoassay for mitophagy dysfunction
PerkinElmer has debuted a no-wash ubiquitin phosphorylation at serine 65 immunoassay for studying defective mitophagy dysfunction associated with Parkinson's...
PerkinElmer immunoassay identifies anti-SARS-CoV-2 compounds
PerkinElmer's AlphaLisa immunoassay was used to support global research for effective COVID-19 therapeutics conducted by the National Center for Advancing...
PerkinElmer launches workstations for COVID-19 detection
PerkinElmer has launched a series of new workstations for SARS-CoV-2 testing.
PerkinElmer launches free COVID-19 data dashboards
PerkinElmer has launched two free, open access COVID-19 data dashboards to speed up the discovery of antivirals and vaccines for the infection.
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter